Research in Focus: Hypertension May Be More Than a Pressure Problem

Written by N. Streawbridge| 29 April 2026

Share this article

What inflammation resolution is teaching us about vascular damage, arterial stiffness and a possible new therapeutic target

For decades, hypertension has largely been explained through a combination of increased sympathetic nervous system activity, activation of the renin–angiotensin–aldosterone system, altered kidney sodium handling and changes in vascular resistance. These mechanisms remain fundamental.


But research is adding another important layer to the picture: chronic immune activation and, particularly, the failure to properly resolve inflammation may help maintain vascular dysfunction and drive the organ damage associated with hypertension.


A recent experimental study examining a compound called Cmpd17b offers an interesting glimpse into this emerging field.


Inflammation is not simply something that has to be “switched off”.


Inflammation is a normal protective response to tissue injury, infection or metabolic stress. Importantly, however, ending an inflammatory response is not passive. The body actively initiates a highly coordinated resolution programme designed to:


  • stop further inflammatory-cell recruitment;
  • remove damaged cells and debris;
  • change macrophage behaviour;
  • promote tissue repair;
  • restore vascular and immune homeostasis.


This involves specialised pro-resolving mediators such as resolvins, protectins, maresins and lipoxins, together with other signalling molecules, regulatory immune cells and processes such as efferocytosis — the clearance of dying cells. When these mechanisms do not work effectively, inflammation may fail to return completely to baseline. Instead, tissues can remain in a state of persistent, low-grade inflammatory activation. A growing body of research suggests that this may be particularly relevant in hypertension.


How could unresolved inflammation affect blood pressure?


Hypertension does not develop through a single pathway. Sympathetic nervous system activation, angiotensin II, aldosterone, oxidative stress, metabolic dysfunction and altered kidney sodium handling all interact. Inflammation appears to sit within this network rather than outside it. For example:


Angiotensin II and oxidative stress

immune activation and inflammatory signalling

reduced endothelial nitric oxide availability

poorer vasodilation

increased vascular resistance


At the same time, persistent inflammatory signalling can promote:


vascular smooth-muscle activation → extracellular-matrix deposition → fibrosis → arterial stiffness


A stiffer artery cannot expand as effectively with each heartbeat. This increases the haemodynamic load on the circulation and can contribute particularly to elevated systolic blood pressure.


The process can therefore become self-reinforcing:


high blood pressure → vascular stress → inflammation and remodelling → increasing arterial stiffness → further haemodynamic stress.


A different approach: resolve rather than simply suppress inflammation


This is where the recent research becomes particularly interesting. Researchers studied compound 17b, or Cmpd17b, a small molecule that activates formyl peptide receptors FPR1 and FPR2.


FPRs are G-protein-coupled receptors involved in immune signalling and the regulation of inflammatory resolution. Rather than acting like a conventional anti-inflammatory drug that broadly suppresses inflammatory pathways, Cmpd17b was designed to favour signalling associated with resolution, cell survival and tissue protection.


Researchers tested the compound in mice in which hypertension was induced using angiotensin II.


What did they find?


Cmpd17b produced a moderate reduction in blood pressure.But something more striking happened in the cardiovascular tissues. Compared with untreated hypertensive mice, animals receiving Cmpd17b showed improvements in cardiovascular function accompanied by reductions in:


  • cardiac fibrosis;
  • aortic fibrosis;
  • vascular calcification;
  • pathological cardiovascular remodelling.


The treatment also influenced mitochondrial function and altered proteins involved in inflammation, calcium regulation, extracellular-matrix organisation and cardiovascular structure.

Proteomic analysis identified approximately 6,000 proteins, allowing the researchers to examine how hypertension altered entire molecular networks rather than individual biomarkers.


Importantly, some of the protein changes affected by Cmpd17b in mice overlapped with proteins known to be dysregulated in human cardiac hypertrophy and adverse aortic remodelling.


The most interesting finding may not have been the fall in blood pressure


The blood-pressure reduction was relatively modest. Yet the improvement in cardiovascular tissue damage was considerably more pronounced.That distinction matters. It suggests that some of the damage associated with hypertension may not simply be the mechanical consequence of blood pushing too strongly against the arterial wall.


There may be parallel biological processes — inflammation, mitochondrial dysfunction, oxidative stress and abnormal tissue remodelling — that continue contributing to cardiovascular risk even when blood pressure itself is being treated.


An accompanying editorial highlighted precisely this possibility: targeting inflammatory resolution could potentially address some of the residual cardiovascular damage that cannot be explained by blood-pressure reduction alone.


Does this mean scientists have discovered a “third cause” of hypertension?


Not quite. Headlines describing inflammation as a newly discovered “third cause of hypertension” make the research sound more revolutionary — and simpler — than it actually is. Inflammatory and immune mechanisms in hypertension have been studied for years. What is newer and particularly interesting is the shift from asking: “How can we suppress inflammation?” to asking: “Why did the inflammatory response fail to resolve?”


These are biologically different questions. The latter opens the possibility of supporting physiological pathways that actively restore immune and vascular balance rather than chronically blocking inflammatory signalling.


A more complete model of hypertension


Instead of thinking about hypertension as the result of only one or two pathways, contemporary research increasingly supports a network model:


Sympathetic nervous system



RAAS / angiotensin II / aldosterone



Kidney sodium and fluid regulation



Endothelial dysfunction



Oxidative stress



Metabolic dysfunction



Immune activation and impaired inflammation resolution



vasoconstriction + sodium retention + reduced nitric oxide + vascular remodelling



arterial stiffness + cardiac and renal damage



persistent hypertension


Different elements of this network may dominate in different people. This is one reason hypertension should not always be viewed as one disease with one mechanism.


The Wildberry Perspective


This research reinforces an important principle in cardiovascular medicine: lowering the number on the blood-pressure monitor and improving the biological health of the cardiovascular system are closely related — but they are not necessarily identical goals.


Blood-pressure control remains fundamental and proven antihypertensive medicines remain essential when indicated. But cardiovascular health also depends on endothelial function, vascular elasticity, mitochondrial function, metabolic health, kidney regulation, inflammatory signalling and the structural integrity of the vascular wall.


The research on Cmpd17b is still preclinical. It was performed predominantly in an angiotensin-II-induced mouse model of hypertension, and the compound is not an established treatment for human hypertension. We therefore cannot assume that the same benefits will occur in patients.


What the study does provide is an intriguing mechanistic direction. Rather than treating chronic inflammation simply as something to suppress, future cardiovascular therapies may increasingly investigate how to restore the body's ability to complete inflammation and return the tissue to homeostasis.


For herbal medicine, this is also an interesting research question. Medicinal plants are frequently described simply as “anti-inflammatory.” A much more sophisticated question is whether particular phytochemicals can influence resolution biology, endothelial signalling, macrophage phenotype, specialised pro-resolving mediator pathways, oxidative stress and tissue remodelling.


That is a considerably more interesting direction for cardiovascular botanical research than asking whether a plant merely lowers a single inflammatory marker.


References


Singh A, et al. Novel formylpeptide receptor 1/2 agonist limits hypertension-induced cardiovascular damage. Cardiovascular Research. 2024;120(11):1336–1352.


Beyond the numbers in treating hypertensive end-organ damage: role of formyl peptide receptor agonist Cmpd17b. Cardiovascular Research. 2024;120(11):1239–1241.


Resolution of inflammation, an active process to restore the immune microenvironment balance: A novel drug target for treating arterial hypertension. Ageing Research Reviews. 2024;99:102352.


Research in Focus examines emerging scientific research relevant to health and medicinal-plant practice. Experimental findings, particularly studies conducted in animals or laboratory models, should not be interpreted as evidence that an intervention is effective or safe in humans. This article is for educational purposes and does not replace individual medical assessment or treatment.


Recent Posts

By Natalia Strawbridge August 31, 2026
How measured botanicals, controlled maceration and written formulas began to give bitters a recognisable pharmaceutical form
By Natalia Strawbridge August 30, 2026
The Two-Nutrient Combination That Improved Strength, Memory and Glutathione
By Natalia Strawbridge August 29, 2026
Understanding what keeps the nervous system on alert — and how to help it recover.
By Natalia Strawbridge August 28, 2026
One vine, five medicinal materials—from ancient remedy to modern pharmacy
By Natalia Strawbridge August 24, 2026
Where the story of bitters begins—not with bitterness, but with spices, herbs and fermentation.
By Natalia Strawbridge August 24, 2026
A patient recently came to Wildberry Clinic because she was repeatedly waking during the night with painful cramps in her legs. Like many people, she assumed the answer was magnesium. She bought a magnesium supplement and started taking it herself. But the cramps continued. That raised a more useful clinical question: Why was she getting nocturnal leg cramps in the first place? Because a night-time leg cramp is a symptom — not a diagnosis. What is a nocturnal leg cramp? A true muscle cramp is a sudden, involuntary and often intensely painful contraction of a muscle. At night it most commonly affects the calf or foot, although other muscles can be involved. The muscle may become visibly or palpably hard, and the episode can last from seconds to several minutes. Occasional nocturnal cramps are extremely common and are often benign. But recurrent, severe or newly developing cramps deserve a broader look. Different possibilities: what could be causing the cramps? 1. Idiopathic nocturnal leg cramps Sometimes there is no identifiable underlying disease. Nocturnal leg cramps become more common with age, and alterations in neuromuscular excitability, muscle shortening, physical activity and biomechanics may all contribute. But “idiopathic” should not simply be assumed before taking a proper history. 2. Chronic venous disease Venous disease is an important part of the differential. Chronic venous insufficiency and varicose veins can be associated with aching, heaviness, swelling and nocturnal cramps . Clues that make us think more carefully about the venous circulation include: visible varicose veins; ankle or lower-leg swelling; legs that feel heavy, aching or tired; symptoms becoming worse after prolonged standing; skin changes around the ankle or lower leg. A cramp alone does not diagnose venous disease, but cramps occurring within this wider pattern deserve vascular assessment. 3. Arterial disease Peripheral arterial disease produces a different pattern. Classically, patients describe calf discomfort when walking that improves with rest. More advanced arterial insufficiency may cause pain at rest, particularly in the foot, together with coldness, colour changes, poor wound healing or reduced peripheral pulses. Not every painful leg symptom at night is therefore a muscle cramp. 4. Neurological causes Muscle contraction ultimately depends on nerve signalling. Peripheral neuropathy, nerve-root irritation or compression and some neuromuscular disorders can therefore produce cramping. We become particularly interested in a neurological cause when cramps occur alongside: numbness; tingling; burning; weakness; altered sensation; muscle wasting; fasciculations; back pain radiating into the leg. Diabetes is relevant here because peripheral neuropathy may alter sensory and motor nerve function. 5. Electrolyte disturbances This is where magnesium belongs — as one part of the differential rather than the default explanation. Abnormalities involving magnesium, potassium, calcium or sodium can affect neuromuscular function. They become more plausible in situations involving: vomiting or diarrhoea; significant sweating; dehydration; restrictive diets; malabsorption; kidney disease; certain medicines. The clinical circumstances matter more than simply assuming that every cramp represents magnesium deficiency. But what about magnesium? Magnesium is essential for normal nerve and muscle function. True magnesium deficiency can increase neuromuscular excitability and may produce cramps, tremor and other symptoms. But taking magnesium because you have cramps does not prove that you were magnesium deficient. And more is not necessarily better. Too much magnesium can also be dangerous The kidneys normally remove excess magnesium, so significant hypermagnesaemia — an abnormally high magnesium concentration in the blood — is uncommon in people with normal kidney function. The risk becomes substantially greater when renal function is impaired, particularly if someone is taking magnesium-containing supplements, laxatives or antacids. Early excessive intake may produce gastrointestinal effects such as diarrhoea. With significant hypermagnesaemia, however, magnesium begins to suppress neuromuscular and cardiovascular function. Symptoms can include: muscle weakness; reduced reflexes; drowsiness; low blood pressure; slowed breathing; abnormalities of cardiac conduction. Severe magnesium toxicity can cause profound hypotension, respiratory depression and, at very high concentrations, cardiac arrest. This is particularly important in people with reduced kidney function , because their ability to excrete magnesium is impaired. So repeatedly increasing magnesium because cramps persist is not a sensible substitute for finding out why the cramps are occurring. 6. Medication-related cramps A medication review is essential. Some medicines may contribute directly to muscle symptoms, while others can change fluid or electrolyte balance. Particular attention should be paid to recent medication changes and to medicines such as diuretics where electrolyte disturbance may occur. Patients should not stop prescribed medicines themselves, but recurrent cramps are a good reason to review the medication list with a clinician. 7. Exercise, muscle fatigue and biomechanics Both too much and too little loading can matter. A sudden increase in exercise, prolonged standing, repetitive muscle use or significant muscular fatigue may precipitate cramps. At the other extreme, prolonged sitting, reduced ankle mobility and shortening or deconditioning of the calf muscles may also contribute. Foot mechanics and footwear are therefore worth considering rather than viewing the problem exclusively through a biochemical lens. 8. Pregnancy Nocturnal leg cramps are common during pregnancy. The cause is likely multifactorial and may include changes in circulation, mechanical loading, fluid distribution and neuromuscular physiology. Again, this does not automatically mean that the mother requires magnesium supplementation. 9. Systemic disease Persistent cramps can occasionally accompany broader medical conditions, including: diabetes; kidney disease; liver disease; thyroid or other metabolic disorders; some neurological diseases. The presence of cramps does not diagnose any of these conditions. It simply means that the surrounding clinical picture matters. And sometimes it isn't a cramp at all One of the most important parts of assessment is establishing what the patient actually means by “cramp.” Night-time leg symptoms can also arise from: restless legs syndrome; peripheral neuropathy; radicular pain from the spine; venous aching or heaviness; arterial rest pain; joint or soft-tissue pain. These conditions require very different approaches. What do we ask? When somebody presents with recurrent nocturnal leg cramps, useful questions include: When did they begin? How often do they occur? Are they in one leg or both? Which muscles are affected? Is there swelling, heaviness or visible venous disease? Is there numbness, tingling or weakness? Does walking bring on calf pain? Has exercise recently changed? Has there been vomiting, diarrhoea, excessive sweating or dehydration? What medications and supplements are being taken? Is there diabetes, kidney disease or another relevant medical condition? Those answers determine whether examination or investigations are needed. What can you do when a cramp happens? For a typical calf cramp, gently stretching the affected muscle can help. Straighten the knee and bring the foot upwards towards the shin to stretch the calf. Getting out of bed and gently walking may also help, as can gentle massage. But recurrent cramps should not simply lead to progressively larger doses of supplements. The Clinical Insight Our patient's magnesium had not solved the problem because “night cramps” and “magnesium deficiency” are not interchangeable diagnoses. Magnesium is one possibility. So are venous disease, neurological problems, medication effects, electrolyte abnormalities, muscle fatigue, pregnancy, systemic disease — or simply idiopathic nocturnal cramping. The useful question is therefore not: “Which magnesium should I take?” It is: “Why is this muscle cramping?” That distinction can completely change the clinical assessment — and sometimes reveal something much more important than a nutritional deficiency. Disclaimer This article is for educational purposes only and is not intended to diagnose or treat any medical condition or replace individual medical assessment. Nocturnal leg cramps have many possible causes, and recurrent, severe, newly developing or unexplained cramps should be assessed in the context of the person’s medical history, medications, examination and, where appropriate, investigations. Supplements, including magnesium, should not be assumed to be necessary solely because cramps are present. Particular caution is required with magnesium supplementation in people with impaired kidney function, as excessive magnesium can accumulate in the blood and, in severe cases, affect neuromuscular, respiratory and cardiovascular function. References Garrison SR, Korownyk CS, Kolber MR, Allan GM, Musini VM, Sekhon RK, Dugré N. Magnesium for skeletal muscle cramps. Cochrane Database of Systematic Reviews. 2020;9:CD009402. doi:10.1002/14651858.CD009402.pub3. The review found that magnesium is unlikely to provide clinically meaningful prevention of idiopathic cramps in older adults; evidence for pregnancy-associated cramps remains uncertain. De Maeseneer MG, Kakkos SK, Aherne T, et al. European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. European Journal of Vascular and Endovascular Surgery. 2022;63(2):184–267. doi:10.1016/j.ejvs.2021.12.024. Relevant to the association of chronic venous disease with symptoms including aching, heaviness, swelling and nocturnal cramps. Lewis JL III. Hypermagnesemia. Merck Manual Professional Edition. Reviewed June 2025; updated December 2025. Hypermagnesaemia is uncommon with normal renal function but occurs particularly in renal failure following exposure to magnesium-containing preparations; severe toxicity can cause hyporeflexia, hypotension, respiratory depression, cardiac conduction abnormalities and cardiac arrest. Lewis JL III. Overview of Disorders of Magnesium Concentration. Merck Manual Professional Edition. Reviewed June 2025. Useful background on magnesium physiology, serum magnesium interpretation and renal regulation of magnesium balance. Clinical herbal medicine grounded in science and individualised care.
By Natalia Strawbridge August 23, 2026
An ancient medicinal food for blood sugar, digestion and cardiovascular health
By Natalia Strawbridge August 20, 2026
How different medical traditions understood, classified and treated head pain
By Natalia Strawbridge August 19, 2026
A new study has shown that an engineered enzyme can remove a specific form of age-associated chemical damage from proteins in human tissues.
By Natalia Strawbridge August 19, 2026
Why normal serum iron can coexist with depleted stores—and how we investigate low ferritin and support healthy iron status at Wildberry Clinic.
Show More